

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

```

NEWS 1          Web Page for STN Seminar Schedule - N. America
NEWS 2 DEC 01    ChemPort single article sales feature unavailable
NEWS 3 JUN 01    CAS REGISTRY Source of Registration (SR) searching
                enhanced on STN
NEWS 4 JUN 26    NUTRACEUT and PHARMAML no longer updated
NEWS 5 JUN 29    IMSCOPROFILE now reloaded monthly
NEWS 6 JUN 29    EPFULL adds Simultaneous Left and Right Truncation
                (SLART) to AB, MCLM, and TI fields
NEWS 7 JUL 09    PATDPAFULL adds Simultaneous Left and Right
                Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS 8 JUL 14    USGENE enhances coverage of patent sequence location
                (PSL) data
NEWS 9 JUL 27    CA/CAPLUS enhanced with new citing references
NEWS 10 JUL 16   GBFULL adds patent backfile data to 1855
NEWS 11 JUL 21   USGENE adds bibliographic and sequence information
NEWS 12 JUL 28   EPFULL adds first-page images and applicant-cited
                references
NEWS 13 JUL 28   INPADOCDB and INPAFAMDB add Russian legal status data
NEWS 14 AUG 08   Improve STN by completing a survey and be entered to
                win a gift card
NEWS 15 AUG 10   Time limit for inactive STN sessions doubles to 40
                minutes

```

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \*

\* Please take a couple of minutes to complete our short survey. Your \*  
 \* name will be entered to win one of five \$20 Amazon.com gift cards. \*  
 \*  
 \* See NEWS 14 for details or go directly to the survey at: \*  
 \* <http://www.zoomerang.com/Survey/?p=WEB229H4S8Q5UL> \*  
 \*  
 \*\*\*\*\*

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 15:13:02 ON 10 AUG 2009

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 15:13:18 ON 10 AUG 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 AUG 2009 HIGHEST RN 1173690-68-0

DICTIONARY FILE UPDATES: 9 AUG 2009 HIGHEST RN 1173690-68-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10576267c.str

10572267



```
chain nodes :
12 15 16 17
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
5-12 7-12 11-15 15-16 15-17
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11
exact/norm bonds :
3-4 4-5 5-12 7-12 15-16 15-17
exact bonds :
1-2 1-5 2-3 11-15
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11
isolated ring systems :
containing 1 : 6 :
```

G1:A,Ak,NH,CO2H

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:CLASS 15:CLASS 16:CLASS 17:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS



L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\19576267d.str



10572267

```
chain nodes :
12 15 16 17
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
5-12 7-12 11-15 15-16 15-17
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11
exact/norm bonds :
3-4 4-5 5-12 7-12 15-16 15-17
exact bonds :
1-2 1-5 2-3 11-15
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11
isolated ring systems :
containing 1 : 6 :
```

G1:A,Ak,NH,CO2H

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:CLASS 15:CLASS 16:CLASS 17:CLASS

L2 STRUCTURE UPLOADED

=> d l2

L2 HAS NO ANSWERS

L2 STR



G1 A,Ak,NH,CO2H

Structure attributes must be viewed using STN Express query preparation.

=> s l2

SAMPLE SEARCH INITIATED 15:15:00 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 58 TO ITERATE

100.0% PROCESSED 58 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 704 TO 1616

PROJECTED ANSWERS: 3 TO 163

L3 3 SEA SSS SAM L2

=> s l2 sss full  
 FULL SEARCH INITIATED 15:15:07 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 953 TO ITERATE

100.0% PROCESSED 953 ITERATIONS 14 ANSWERS  
 SEARCH TIME: 00.00.01

L4 14 SEA SSS FUL L2

=> FIL HCAPLUS		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	186.84	187.06

FILE 'HCAPLUS' ENTERED AT 15:15:12 ON 10 AUG 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Aug 2009 VOL 151 ISS 7  
 FILE LAST UPDATED: 9 Aug 2009 (20090809/ED)  
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009  
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>


This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> s l4  
 L5 4 L4  
 => d l5 ibib abs hitstr tot

L5 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2007:259908 HCAPLUS  
 DOCUMENT NUMBER: 146:309313  
 TITLE: Use of aminoarylthiazole and aminoaryloxazole dual  
 c-kit/FGFR3 inhibitors for treating multiple myeloma  
 INVENTOR(S): Moussy, Alain; Kinet, Jean-Pierre  
 PATENT ASSIGNEE(S): Ab Science, Fr.  
 SOURCE: PCT Int. Appl., 31pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007026251	A2	20070308	WO 2006-IB3111	20060713
WO 2007026251	A3	20070712		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA EP 1904065 A2 20080402 EP 2006-820848 20060713 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR US 20080207572 A1 20080828 US 2008-995592 20080114 US 20080207572 A1 20080828 US 2005-698937P P 20050714 PRIORITY APPLN. INFO.: WO 2006-IB3111 W 20060713				
OTHER SOURCE(S): MARPAT 146:309313				
AB The invention relates to a method for treating Multiple Myeloma, FGFR3+ myeloma, especially relapsed or refractory multiple myeloma (4/14) expressing FGFR3, comprising administering a dual c-kit/FGFR3 inhibitor, e.g. 2-aminoarylthiazoles and 2-aminoaryloxazoles. IT 928298-12-8 928298-16-2 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (aminoarylthiazole and aminoaryloxazole dual c-kit/FGFR3 inhibitors for treatment of multiple myeloma) RN 928298-12-8 HCAPLUS CN Benzamide, N-(3-chlorophenyl)-4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]- (CA INDEX NAME)				




RN 928298-16-2 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-,  
(11 $\beta$ ,16 $\alpha$ )-, mixt. with N-(3-chlorophenyl)-4-methyl-3-[[5-(4-  
pyridinyl)-2-oxazolyl]amino]benzamide (CA INDEX NAME)

CM 1

CRN 928298-12-8

CMF C22 H17 Cl N4 O2




CM 2

CRN 50-02-2

CMF C22 H29 F O5

Absolute stereochemistry.



OS.CITING REF COUNT: 1

THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L5 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:395287 HCAPLUS

DOCUMENT NUMBER: 142:447205

TITLE: Preparation of 2-(arylamino)oxazole derivatives as inhibitors of c-kit, bcr-abl, FGFR3, and/or Flt-3  
 INVENTOR(S): Moussy, Alain; Wermuth, Camille; Grierson, David; Benjahad, Abdellah; Croisy, Martine; Ciufolini, Marco; Giethlen, Bruno

PATENT ASSIGNEE(S): Science AB, Fr.; Centre National de la Recherche Scientifique CNRS; Institut Curie

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040139	A2	20050506	WO 2004-IB3698	20041022
WO 2005040139	A3	20051013		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004283162	A1	20050506	AU 2004-283162	20041022
CA 2542909	A1	20050506	CA 2004-2542909	20041022
EP 1684750	A2	20060802	EP 2004-791783	20041022
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004015467	A	20061219	BR 2004-15467	20041022
JP 2007509130	T	20070412	JP 2006-536215	20041022
CN 1950347	A	20070418	CN 2004-80037159	20041022
US 20070142390	A1	20070621	US 2006-576267	20060418
IN 2006DN02206	A	20070420	IN 2006-DN2206	20060421
MX 2006004581	A	20061120	MX 2006-4581	20060424
ZA 2006004041	A	20070425	ZA 2006-4041	20060519
NO 2006002308	A	20060522	NO 2006-2308	20060522
KR 2006118500	A	20061123	KR 2006-710034	20060523
PRIORITY APPLN. INFO.:			US 2003-513214P	P 20031023
			WO 2004-IB3698	W 20041022
OTHER SOURCE(S):		CASREACT 142:447205; MARPAT 142:447205		
GI				





AB Title compds. I [R1, R2, R3, and R4 independently = H, halo, alkyloxy, etc.; R5 = H, (un)substituted linear or branched alkyl, COR8, etc.; R6 and R7 independently = H, halo, (un)substituted aryl, etc.; R8 = (un)substituted-aryl, -alkyl, -heteroaryl, etc.; R9 and/or R10 = H, (un)substituted-alkyl, -aryl, etc.; X = (un)substituted-alkyl, C:OY, NR9R10, etc.; Y = NR9R10, NHR9R10, (un)substituted-aryl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors. Thus, e.g., 3-acetyl-pyridine was brominated and subsequently converted into the azido derivative, which was cyclized with 2-methyl-5-nitrophenyl isocyanate followed by a reduction to the resp. amine derivative, which could be further elaborated to


give II. The activity of I was evaluated in tyrosine kinase inhibition assays and it revealed that selected compds. of the invention possessed IC50 values of less than 1  $\mu$ M. I should prove useful in the treatment of neoplastic diseases. Pharmaceutical compns. comprising I are disclosed.

IT 851318-26-8P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of 2-(arylamino)oxazole derivs. as inhibitors of c-kit, bcr-abl, FGFR3, and/or Flt-3)

RN 851318-26-8 HCAPLUS


CN Benzamide, N-(4-cyanophenyl)-4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]- (CA INDEX NAME)



IT 851318-27-9P 851318-28-0P 851318-29-1P  
 851318-30-4P 851318-31-5P 851318-32-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of 2-(arylamino)oxazole derivs. as inhibitors of c-kit,  
 bcr-abl, FGFR3, and/or Flt-3)  
 RN 851318-27-9 HCAPLUS  
 CN Benzamide, N-[3-(dimethylamino)phenyl]-4-methyl-3-[[5-(4-pyridinyl)-2-  
 oxazolyl]amino]- (CA INDEX NAME)




RN 851318-28-0 HCAPLUS  
 CN Benzamide, N-[2-(dimethylamino)ethyl]-4-methyl-3-[[5-(3-pyridinyl)-2-  
 oxazolyl]amino]- (CA INDEX NAME)




RN 851318-29-1 HCAPLUS  
 CN Benzamide, N-(3-fluoro-4-methylphenyl)-4-methyl-3-[[5-(4-pyridinyl)-2-

oxazolyl]amino]- (CA INDEX NAME)




RN 851318-30-4 HCAPLUS

CN Benzamide, N-(3-chlorophenyl)-4-methyl-3-[[5-(3-pyridinyl)-2-oxazolyl]amino]- (CA INDEX NAME)




RN 851318-31-5 HCAPLUS

CN Benzamide, 4-methyl-N-(phenylmethyl)-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]- (CA INDEX NAME)



RN 851318-32-6 HCAPLUS

CN Benzamide, N-[(4-methoxyphenyl)methyl]-4-methyl-3-[[5-(4-pyridinyl)-2-oxazolyl]amino]- (CA INDEX NAME)





OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD  
(7 CITINGS)  
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS ON STN  
ACCESSION NUMBER: 2004:1082034 HCAPLUS  
DOCUMENT NUMBER: 142:56293  
TITLE: P-38 inhibitors  
INVENTOR(S): Dong, Qing; Pierre, Fabrice; Wang, Jianqiang  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 76 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040254236	A1	20041216	US 2004-860768	20040602
AU 2004251668	A1	20050106	AU 2004-251668	20040602
AU 2004251668	B2	20080320		
CA 2528438	A1	20050106	CA 2004-2528438	20040602
WO 2005000298	A2	20050106	WO 2004-US17580	20040602
WO 2005000298	A3	20050303		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1635824	A2	20060322	EP 2004-754233	20040602
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004010905	A	20060627	BR 2004-10905	20040602
CN 1829513	A	20060906	CN 2004-80021972	20040602
JP 2006526656	T	20061124	JP 2006-515154	20040602
MX 2005013075	A	20060317	MX 2005-13075	20051202
IN 2005CN03236	A	20070914	IN 2005-CN3236	20051202
PRIORITY APPLN. INFO.:			US 2003-475662P	P 20030603

US 2003-531541P  
WO 2004-US17580P 20031219  
W 20040602OTHER SOURCE(S):  
GI

MARPAT 142:56293



AB 5-Membered heterocycle-based p38 kinase inhibitors I (R1 = H, Me, halogen, OH, lower alkyl, lower cycloalkyl, lower alkynyl, CF3, OMe, OCF3, CN, NH2, alkylamine, alkoxy; R2 = alkyl, substituted alkyl, lower cycloalkyl, halo, CF3, OCF3, alkoxy, alkylamine, sulfoxy, sulfone, amide, and n = 0, 1, or 2; R3 = H, alkyl, alkoxy, substituted alkyl, cycloalkyl, heteroaryl, heterocycle; Y = a single bond, C(O)NH, NHC(O), NHC(O)NH, SO2NH, NHSO2, C(O); B = a 5-membered heterocyclic ring system optionally substituted; Q = a single bond, O, S, alkylamine, SO, SO2, C(O), CO(O), C(O)NH, CH2; D = a monocyclic or bicyclic ring system) are prepared for the treatment of inflammatory and autoimmune diseases. Thus, to 3-amino-N-methoxy-4-methyl-benzamide in CH2Cl2 was added benzoyl isothiocyanate, and N, N-diisopropylethylamine followed by treatment with hydrazine monohydrate to give II. II had an IC50 of less than 50 nM against p38a.


IT 808737-97-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of p-38 kinase inhibitors for the treatment of inflammatory and autoimmune diseases)

RN 808737-97-5 HCAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[(5-phenyl-2-oxazolyl)amino]- (CA INDEX NAME)





OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)


L5 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2002:755249 HCAPLUS

DOCUMENT NUMBER: 137:263025  
 TITLE: Preparation of substituted oxazoles as IMPDH inhibitors  
 INVENTOR(S): Liu, Chunjian; Dhar, T. G. Murali; Gu, Henry H.; Iwanowicz, Edwin J.; Leftheris, Katerina; Pitts, William J.; Herpin, Timothy F.; Pi, Zulan; Bisacchi, Gregory S.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S. Ser. No. 428,432.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020143176	A1	20021003	US 2001-997963	20011129
US 6596747	B2	20030722		
US 6399773	B1	20020604	US 1999-428432	19991027
WO 2003047512	A2	20030612	WO 2002-US38038	20021127
WO 2003047512	A3	20031016		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002352950	A1	20030617	AU 2002-352950	20021127
EP 1448187	A2	20040825	EP 2002-789910	20021127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:				
			US 1998-106186P	P 19981029
			US 1999-428432	A2 19991027
			US 2001-997963	A 20011129
			WO 2002-US38038	W 20021127
OTHER SOURCE(S):	MARPAT 137:263025			
GI				



- AB Title compds. I [D = mono/bicyclic (hetero)cyclic ring; A = R3, R4; R3 = 5-6-membered (un)saturated heterocyclic ring; R4 = H, halo, NO, CF3, alkyl, alkoxy, etc.; R = H, alkyl; R1-2 = H, halo, NO2, alkyl, etc.; B = mono/bicyclic (hetero)cyclic ring system] were prepared
- 5-(4-Amino-2-methoxyphenyl)oxazole was reacted with di-Ph cyanocarbonimide (CH3CN, reflux, 40 h) to give an intermediate which was reacted with 2-hydrazinopyridine to afford II. I are effective inhibitors of IMPDH enzyme and/or serine protease factor VIIa.
- IT 463941-53-9P, 3-[[5-[2-[[2-(Aminoacetyl)methylamino]methyl]phenyl]oxazol-2-yl]amino]-N-methylbenzamide
- RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
- (IMPDH inhibitor; preparation of substituted oxazoles as IMPDH inhibitors)
- RN 463941-53-9 HCAPLUS
- CN Benzamide, 3-[[5-[2-[[3-amino-2-oxopropyl]amino]methyl]phenyl]-2-oxazolyl]amino]-N-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS

## RECORD (12 CITINGS)

=&gt; log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

36.81

223.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.28

-3.28

STN INTERNATIONAL LOGOFF AT 15:18:09 ON 10 AUG 2009